oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Joint Diseases
Conditions
Joint Diseases, Arthritis, Osteoarthritis
Trial Timeline
Oct 1, 2008 → Jul 1, 2009
NCT ID
NCT00784277About oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo
oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo is a phase 3 stage product being developed by Johnson & Johnson for Joint Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00784277. Target conditions include Joint Diseases, Arthritis, Osteoarthritis.
What happened to similar drugs?
1 of 1 similar drugs in Joint Diseases were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00784277 | Phase 3 | Completed |
Competing Products
6 competing products in Joint Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine | SI-BONE | Approved | 29 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 24 |
| etanercept + placebo | Pfizer | Phase 2 | 35 |
| VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN | Pfizer | Phase 2 | 31 |
| HOE140 Icatibant | Sanofi | Phase 2 | 35 |
| Methylprednisoloneacetate + Lidocaine | Lundbeck | Phase 2 | 32 |